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Technical Note
The Performance of a Commercial Radioligand 
Binding Assay for the Epidermal Growth Factor 
Receptor is Comparable to the EORTC Standard
Assay
C . O b e r k a n in s , A .  G e u r ts - M o e s p o t , R .  Z e il l in g e r , F .  K u r y , R .E .  L e a k e  a n d
T . J .  B e n r a a d
T h e  p re se n ce  of epidermal growth factor receptors (EGF-R) 
was recognised to be indicative of poor prognosis in human 
breast cancer, although its significance as a prognostic marker 
for response to therapy and progression of tumours has remained 
a matter of controversy [1-4]. A variety of methods were 
developed to quantify levels of EGF-R expression, in particular 
binding assays with radiolabelled or biotinylated ligands, immu- 
noenzymatic assays, immunohistochemistry, and mRNA analy­
sis. The majority of studies were based on radioligand binding 
assays, but even among these, a great divergence of results was 
apparent. These variations were, at least in part, caused by the 
lack of standardised methods for sample processing, radiolabel 
preparation, receptor analysis, and measurement of reference 
parameters, such as protein concentration.
We performed a series of experiments at a quality control 
laboratory of the European Organization for Research and 
Treatment of Cancer (EORTC) Receptor Study Group 
(University Hospital Sint Radboud, Department of Experimen­
tal and Chemical Endocrinology, Nijmegen, The Netherlands) 
to assess the performance of a commercially available, multiple 
point radioligand binding assay for EGF-R (EGF-Receptor 
“Scatchard” Assay, ViennaLab, Vienna, Austria) compared 
with the method that has recently been recommended by the 
Receptor Study Group as the common methodology for assaying 
EGF-R [5-7]. The study was designed to examine whether these 
currently accepted common standards are met by a ready-to-use 
kit that is available for any non-specialist laboratory.
The EORTC assay for EGF-R was performed as described in 
detail elsewhere [5, 7]. The ViennaLab “EGF-Receptor Scatch­
ard Assay” was used according to the protocol provided. The
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two assays have certain characteristics in common (e.g. the 
use of enzymatically labelled [125I]-EGF at eight increasing 
concentrations), but differ in several important respects, such as 
incubation conditions and the type of reagents used for the 
separation of bound and unbound tracer. Receptor values from 
both assays were calculated by Scatchard analysis using a curve- 
fit computer program (“Receptor”) designed by H.A. Ross 
(University Hospital Nijmegen, The Netherlands). EGF-R 
analyses, resulting in interpretable Scatchard plots, were classi­
fied as positive.
Initially, the within (intra-) and between (inter-) assay repro­
ducibilities of both methods were analysed using human placenta 
membrane preparations [8]. The data obtained, expressed as 
coefficients of variation (C. V.) in Table 1, confirmed both assays 
to be highly reproducible and suitable for routine applications. 
In a subsequent series of tests, one hundred primary breast 
carcinomas were processed in accordance with EORTC re­
commendations for steroid hormone receptor assays [9]. Mem­
brane suspensions were obtained as previously described [7], 
and analysed for protein content (Membrane Protein Assay, 
ViennaLab; range of results: 0.32-2.44 mg/ml) and for EGF-R, 
in parallel with both the EORTC and the ViennaLab assay 
(Table 1). Slightly more than half of the tumours were found to 
be EGF-R positive (EORTC: 56%, ViennaLab: 58%). With the 
exception of one sample (>1000 fmol/mg), EGF-R values were 
between 1 and 200 fmol/mg of membrane protein. By applying 
the Spearman rank order correlation test, data were shown to be 
in excellent agreement (r = 0.9084, P  < 10-6). Upon classifi­
cation of results into “EGF-R-positive” and “EGF-R-negative”, 
accordance of data was found in 92 of 100 samples. Both assays 
exhibited very low non-specific tracer binding (EORTC: 2.5%, 
ViennaLab: 1.5%, when expressed as the ratio of non-specificaliy 
bound tracer to free tracer), which is a major prerequisite for a 
sufficiently high sensitivity.
Based on these results, it can be concluded that both assays 
generate comparable data, and that it is possible to utilise a 
commercially available assay for routine measurement of EGF-R 
in human tumour specimens according to EORTC standards.
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Table 1. Comparison o fE O R T C  and ViennaLab assay
EORTC assay ViennaLab assay
Intra-assay reproducibility* n = 5 (sample A) n = 5 (sample A)
Mean EGF-R value 30.2 fmol/ml 2 .^0 fmol/ml
S.D. 2.1 fmol/ml 1.3 fmol/ml
C.V. 7.1% 4.4%
Inter-assay reproducibility* n = 9 (sample B) n = 9 (sample C)
Mean EGF-R value 98.6 fmol/ml 571 fmol/ml
S.D. 8.1 fmol/ml 32 fmol/ml
C.V. 8.2% 5.7%
EGF-R values! 
Positives n = 56 n = 58
Median value 18.2 fmol/mg 12.9 fmol/mg
Mean value 49.6 fmol/mg 45.5 fmol/mg
Range 1.6-1036 fmol/mg 1.6-1084 fmol/mg
Correlation of resultsf 
EORTC +/VL + (n 
EORTC +/VL - (n 
EORTC -/VL + (n 
EORTC-/VL - (n
53)
3)
5)
39)
Accordance of EGF-R positive/negative in 92% of samples 
Spearman rank order correlation of overall positives (n — 53):
r *  0.9084, P <  0.000001
Non-specific bindingf (median bound/free ratio) 2.5% 1.5%
*The intra (within) and inter (between) assay reproducibilides of both methods were determined by a single person analysing human 
placenta membrane preparations for the indicated number of repeats («) in one single (intra-assay) or in multiple (inter-assay) sets of 
assays. (S.D., standard deviation; C. V., coefficient of variation); f A total of 100 primary breast carcinomas were analysed in parallel 
using both assays, and EGF-R values were calculated by Scatchard analysis* Data were compared using basic and non-parametric 
statistics. (Spearman rank order test: r, correlation coefficient; P , significance level.)
For a final decision on the value of EGF-R as a prognostic 
parameter, clinical data from a sufficiently large number of 
patients will have to be compared to EGF-R levels obtained 
under standardised assay conditions- The present study opens 
the possibility for oncologists and routine diagnostic laboratories 
to acquire EGF-R data by means of a commercially available 
assay according to European standards set by the EORTC.
1. Sainsbury JRC, Malcolm AJ, Appleton DR, Farndon JR, Harris 
AL. Presence of epidermal growth factor receptor as an indicator of 
poor prognosis in patients with breast cancer. J  Clin Pathol 1985,38, 
1225-1228.
2. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris 
AL. Epidermal growth factor receptor status as predictor of early 
recurrence of and death from breast cancer. Lancet 1987, 1, 
1398-1402.
3. Gullick WJ. Prevalence of aberrant expression of the epidermal 
growth factor receptor in human cancers. Br Med Bull 1991, 47, 
87-98.
4. Klijn JGM, Berns PMJJ, Schmitz PLM, Foekens JA. The clinical
significance of epidermal growth factor receptor (EGF-R) in human 
breast cancer: a review on 5232 patients. EndocrRev 1992, 13, 3-17.
5. Benraad TJ, Foekens JA. Hydroxyapatite assay to measure epidermal 
growth factor receptor in human primary breast tumours. A Clin 
Biochem 1990,27,272-273.
6. Koenders PG, Faverly D , Beex LVAM, Bruggink EDM, Kienhuis 
CBM, Benraad TJ. Epidermal growth factor receptors in human 
breast cancer: a plea for standardisation of assay methodology. EurJ
Cancer 1992,28,693-697.
7. Koenders PG, Beex LVAM, Geurts-Moespot A, Heuvel JJTM, 
Kienhuis CBM, Benraad TJ. Epidermal growth factor receptor- 
negative tumors are predominantly confined to the subgroup of 
estradiol receptor-positive human primary breast cancers. Cancer Res 
1991, 51,4544-4548.
8. Kienhuis CBM, Heuvel JJTM, Ross HA, Swinkels LMJM, Foekens 
JA, Benraad TJ. Six methods for direct radioiodination of mouse 
epidermal growth factor compared: effect of nonequivalence in 
binding behavior between labeled and unlabeled ligand. Clin Chern
1991,37,1749-1755.
9. EORTC Breast Cancer Cooperative Group. Revision of the standards 
for the assessment of hormone receptors in human breast cancer; 
report of the second EORTC workshop, held on 16-17 March 
1979, in the Netherlands Cancer Institute. E u r J  Cancer 1980, 16, 
1513-1515.
